What is Amylyx Pharmaceuticals Inc (AMLX) stock price today?

Amylyx Pharmaceuticals Inc (AMLX) currently trades at $14.73 per share. The stock has a market capitalization of $1.69B and a P/E ratio of —x.

Is AMLX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Amylyx Pharmaceuticals Inc has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Amylyx Pharmaceuticals Inc's revenue and earnings?

Amylyx Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $-665000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-1.48.

AMLX

Amylyx Pharmaceuticals Inc

NASDAQ: AMLX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$14.73

-3.09% today

Updated 2026-05-08

Market cap

$1.69B

P/E ratio

—

P/S ratio

0.66x

EPS (TTM)

$-1.48

Dividend yield

—

52W range

$4 – $19

Volume

1.1M

Market cap

$1.69B

P/E ratio

—

P/S ratio

0.66x

EPS (TTM)

$-1.48

Dividend yield

—

52W range

$4 – $19

Volume

1.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →194 stocks currently score above 75

Price targets

Analyst target

$23.30

+58.18%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy11 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-36.88M

- Revenue declining -99.60% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$22.23M	$380.79M	$87.37M	$0.00	$-665000.00
Net income	$-198.38M	$49.27M	$-301.74M	$-144.74M	$-41.28M
EPS	—	—	—	—	$-1.48
Free cash flow	$-182.40M	$10.68M	$-167.80M	$-123.48M	$-36.88M
Profit margin	-892.38%	12.94%	-345.36%	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
AMLX	$1.69B	31	3.7	3.0	5.0	5.0	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-37.47%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-19.74%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+40.60%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Amylyx Pharmaceuticals Inc trades at $14.73. Our Smart Value Score of 31/100 indicates the stock is weak. TTM revenue stands at $-665000.00.

Frequently asked questions

What is Amylyx Pharmaceuticals Inc's stock price?

Amylyx Pharmaceuticals Inc (AMLX) trades at $14.73.

Is Amylyx Pharmaceuticals Inc overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of Amylyx Pharmaceuticals Inc (AMLX)?

The analyst target price is $23.30, representing +58.2% upside from the current price of $14.73.

What is Amylyx Pharmaceuticals Inc's revenue?

TTM revenue is $-665000.00.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio0.66x

ROE-63.30%

Beta-0.10

50D MA$15.42

200D MA$13.24

Shares out0.11B

Float0.08B

Short ratio—

Avg volume1.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

AMLX vs LLY →AMLX vs JNJ →AMLX vs ABBV →Stock screener →